SpaceX To Rally Around 85%? Here Are 10 Top Analyst Forecasts For Friday
Wall Street analysts raised targets for MSTR, FOXA, NRIX, ZETA and TWLO, while cutting targets for CAMT and DVN.
Stocks · News reference
CORRECTION: Nurix Therapeutics Q3 EPS $4.73 Beats $3.98 Estimate, Sales $673.064M Beat $411.481M Estimate
Nurix Therapeutics (NASDAQ:NRIX) reported quarterly earnings of $4.73 per share which beat the analyst consensus estimate of $3.98 by 18.84 percent. This is a 559.22 percent increase over losses of $(1.03) per share
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HC Wainwright & Co. Maintains Buy on Nurix Therapeutics, Raises Price Target to $36
HC Wainwright & Co. analyst Robert Burns maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $34 to $36.
RBC Capital Maintains Outperform on Nurix Therapeutics, Lowers Price Target to $35
Oppenheimer Maintains Outperform on Nurix Therapeutics, Raises Price Target to $32
Oppenheimer analyst Kostas Biliouris maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $28 to $32.